October was Breast Cancer Awareness Month (BCAM), which is an annual initiative designed to help raise awareness of important information regarding breast health and breast cancer risk factors. To coincide with this year’s BCAM campaign, we would like to announce the expansion of one of our partnered CRO vendors, Cellesce, into patient-derived breast cancer organoids, which will be made available for use in early-stage drug discovery towards the end of 2020.
Organoid Vendor - Cellesce
Cellesce has developed a proprietary bioprocess technology to expand patient-derived organoid (PDO) lines at large scale. These organoids accurately recapitulate the original patient biopsy, including disease-causing genetic mutations, and are produced in sufficient quantity, quality and consistency to support drug applications for compound screening. Cellesce’s technology minimises manual handling time and maximises result reproducibility, with the ultimate goal of positioning organoid technology as a cost-effective model for use in preclinical oncology studies. To date, Cellesce has focused its development efforts on 10 colorectal cancer patient-derived organoid lines using their specialised bioprocess technology. Following the success of these models, Cellesce has now expanded its product portfolio to include patient-derived breast cancer organoids, with a range of other models (including normal intestine, normal colon, lung cancer and liver cancer) in the development pipeline.
Patient-derived breast cancer organoids
A number of new and unique breast cancer organoid lines have been established from primary patient biopsies or from patient-derived xenograft (PDX) tissue, including a variety of breast cancer subtypes and TNM stages, such as ER+, HER2+ and triple negative. These organoid lines have never been cultured in 2D adherent conditions, and thus faithfully represent the tumour from which they were derived. They are specifically designed to provide good mimicry of real-life patient environments, including more accurate genomic profiling and cellular heterogeneity simulation.
Image taken from the Cellesce Breast Cancer flyer
Cellesce provide a range of organoid model characterisation including mutation profiling, immunohistochemistry and standard of care validation, and the vendor ensures all organoids are free from mycoplasma and viral pathogens. In addition, all models are designed in an easy-to-use format with organoids delivered to users in frozen cryovials ready for seeding, and media conditions are established with full use protocols provided by Cellesce. Technical support is also available on demand. All these characteristics allow for maximum consistency and reproducibility across organoid cultures, whilst still maintaining the phenotype and genotype of the starting tissue.
“By working with Cellesce, we’re making it easier for oncology researchers and data providers to collaborate and speed up the development of new treatments. Cellesce’s expansion into breast cancer organoids will help to further enhance our web-based solution by increasing the range of models we can offer oncology researchers.”
Dr Fiona Nielsen, Co-Founder and CEO of Repositive
Repositive works by connecting our CRO partners with biopharma researchers looking for cancer models for their preclinical oncology studies. By putting researchers in contact with the right CROs, we are helping to accelerate cancer drug development to bring new treatments and cures to patients.